News|Articles|August 8, 2024
Biopharmaceutical Frontiers
Author(s)Solvias
Daniel Galbraith, Chief Scientific Officer (CSO) of Solvias provided a comprehensive picture to Pharmaceutical Technology of the current landscape of cell and gene therapy advancements. The discussion covers important regulatory guidance, technological landmarks, and how Solvias is impacting the current market.
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Related Content
Trending on Pharmaceutical Technology
1
Using AI and Molecular Dynamics to Overcome the Poor Solubility Challenge
2
Targeted high resolution metabolite screening workflows
3
Application of alternative electron-based fragmentation for identification of drug metabolites and quantification of complex peptide therapeutics
4
Confident characterization and identification of glucuronide metabolites using diagnostic fragments from electron activated dissociation (EAD)
5
